Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × rilotumumab × Clear all
NCT00719550 2013-12-05

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Amgen

Phase 1/2 Completed
130 enrolled
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡